Tumor growth in patients with tuberous sclerosis complex on the ketogenic diet

Brain and Development

Volumn 32, Issue 4, 2010, Pages 318-322

  Chu Shore, Catherine J ^a   Thiele, Elizabeth A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Angiomyolipoma; Ketogenic diet; mTOR; Nutrition; Subependymal giant cell tumor; TSC; Tuberous sclerosis complex

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; RAPAMYCIN;

ADOLESCENT; ADULT; ANGIOMYOLIPOMA; ARTICLE; BRAIN TUMOR; CANCER SURGERY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENE MUTATION; HAMARTOMA; HUMAN; INTRACTABLE EPILEPSY; KETOGENIC DIET; KIDNEY ARTERY EMBOLIZATION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL STATUS; PRESCHOOL CHILD; SCHOOL CHILD; SUBEPENDYMAL GIANT CELL TUMOR; TREATMENT DURATION; TUBEROUS SCLEROSIS; TUMOR GROWTH;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HUMANS; KETOGENIC DIET; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; TUBEROUS SCLEROSIS; YOUNG ADULT;

EID: 77549087603     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.braindev.2009.04.009     Document Type: Article

References (25)

1. Dabora S.L., Jozwiak S., Franz D.N., et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 68 (2001) 64-80
2. Sancak O., Nellist M., Goedbloed M., et al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur J Hum Genet 13 (2005) 731-741
3. Crino P.B., Nathanson K.L., and Petri Henske E. The tuberous sclerosis complex. NEJM 355 (2006) 1345-1356
4. Sarbassov D.D., Ali S.M., and Sabatini D.M. Growing roles for the mTOR pathway. Curr Opin Cell Biol 17 (2005) 596-603
5. Sabatini D.M. MTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6 (2006) 729-734
6. Dann S.G., Selvaraj A., and Thomas G. MTOR complex1-S6K1 signaling: at the crossroads of obesity, diabetes, and cancer. Trends Mol Med 13 (2007) 252-259
7. Guertin D.A., and Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell Rev 12 (2007) 9-22
8. Inoki K., Zhu T., and Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 (2003) 577-590
9. Gao X., Zhang Y., Arrazola P., Hino I., Kobayashi T., Yeung R.S., et al. TSC tumour suppressor proteins antagonize amino-acid-TOR signaling. Nat Cell Biol 4 (2002) 699-704
10. Smith E.M., et al. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J Biol Chem 280 (2005) 18717-18727
11. Kimball S.R., and Jefferson L.S. Signaling pathways and molecular mechanisms through which branched-chain amino acids mediate translational control of protein synthesis. J Nutr 136 (2006) 227S-231S
12. Um S.H., D'Alessio D., and Thomas G. Nutrient overload, insulin resistance, and ribosomal S6 kinase 1. Cell Metabol 3 (2006) 393-402
13. Franz D.N., Leonard J., Tudor C., et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59 (2006) 490-498
14. Wieneck R., Fackler I., Linsenmaier U., et al. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis 48 (2006) e27-e29
15. Herry I., Neukirch C., Debray M.P., et al. Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex. Eur J Intern Med 18 (2007) 76-77
16. Bissler J.J., McCormack F.X., Young L.R., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. NEJM 358 2 (2008) 140-151
17. Peng T., Golub T.R., and Sabatini D.M. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol 22 (2002) 5575-5584
18. Thiele E.A. Managing epilepsy in tuberous sclerosis complex. J Child Neurol 19 (2004) 680-686
19. Webb D.W., Fryer A.E., and Osborned J.P. Morbidity associated with tuberous sclerosis: a population study. Dev Med Child Neurol 38 (1996) 146-155
20. Kossoff E.H., Thiele E.A., Pfeifer H.H., McGrogan J.R., and Freeman J.M. Tuberous sclerosis complex and the ketogenic diet. Epilepsia 46 (2005) 1684-1686
21. Freeman J.M., Kossoff E.H., and Hartman A.D. The ketogenic diet: one decade later. Pediatrics 119 (2007) 535-543
22. Paul E., and Thiele E. Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis. NEJM 358 (2008) 190-192
23. Adriaenson ME, Shaefer-Prokop CM, Stijnen T, Duyndam DA, Zonnenberg BA, Prokop M. Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature. Eur J Neurol. 2009; PMID: 19236458.
24. Rakowski S.K., Winterkorn E.B., Paul E., Steele D.J.R., Halpern E.F., and Thiele E.A. Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors. Kidney Int (2006) 1777-1782
25. Kim D.H., Sarbassov D.D., Ali S.M., et al. MTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110 (2002) 163-175